REGULAR CONTENT
Final ID
528
Type
Original Scientific Research-Oral or Pos
Authors
A Moturu1, D Ashton1
Institutions
1Texas Children's Hospital, Houston, TX
Purpose
Hematology and Oncology patients often receive a peripherally inserted central line (PICC) for long term venous access during the course of their treatment. This retrospective study was designed to compare and analyze PICC line complication rates within groups of oncology patients including bone marrow transplant (BMT) vs non-BMT patients and acute myeloid leukemia (AML) patients vs non-AML patients.
Materials & Methods
Electronic health records of a large children's hospital were accessed to gather PICC line placement and maintenance data from January 2014 to December 2015. Data was collected on indication for PICC, PICC line dwell time, complication history, and procedure details. Data was used to find infection rates per thousand line days for various groups of hematology/oncology patients. The data was statistically analyzed using a chi-squared test. Groups compared were BMT vs non-BMT patients and AML vs non-AML patients.
Results
504 PICC lines were placed in hematology/oncology patients with an average dwell time of 75 days. There was an infection rate of 1.37 infections per thousand line days.165 BMT patients had PICC lines for an average of 88.3 days and an infection rate of 0.96 infections per thousand line days. 339 Non-BMT patients had PICC lines for an average of 66.9 days and an infection rate of 1.63 infections per thousand line days. The lower infection rate in non-BMT patients is not statistically significant (p = 0.35, α = 0.1).93 AML patients had PICC lines for an average of 82.7 days and an infection rate of 1.82 infections per thousand line days. 441 non-AML patients had PICC lines for an average of 73.6 days and an infection rate of 1.26 infections per thousand line days. The higher infection rate in AML patients is statistically significant (p = 0.09, α = 0.1).
Conclusions
Both BMT patients and AML patients have a high risk of infection due to their immunocompromised status. AML patients do have a higher rate of infection compared to the overall oncology cohort, however BMT patients do not have a higher rate of infection. This may be due to improved care for their PICC during hospitalization for their bone marrow transplantation.
Final ID
528
Type
Original Scientific Research-Oral or Pos
Authors
A Moturu1, D Ashton1
Institutions
1Texas Children's Hospital, Houston, TX
Purpose
Hematology and Oncology patients often receive a peripherally inserted central line (PICC) for long term venous access during the course of their treatment. This retrospective study was designed to compare and analyze PICC line complication rates within groups of oncology patients including bone marrow transplant (BMT) vs non-BMT patients and acute myeloid leukemia (AML) patients vs non-AML patients.
Materials & Methods
Electronic health records of a large children's hospital were accessed to gather PICC line placement and maintenance data from January 2014 to December 2015. Data was collected on indication for PICC, PICC line dwell time, complication history, and procedure details. Data was used to find infection rates per thousand line days for various groups of hematology/oncology patients. The data was statistically analyzed using a chi-squared test. Groups compared were BMT vs non-BMT patients and AML vs non-AML patients.
Results
504 PICC lines were placed in hematology/oncology patients with an average dwell time of 75 days. There was an infection rate of 1.37 infections per thousand line days.165 BMT patients had PICC lines for an average of 88.3 days and an infection rate of 0.96 infections per thousand line days. 339 Non-BMT patients had PICC lines for an average of 66.9 days and an infection rate of 1.63 infections per thousand line days. The lower infection rate in non-BMT patients is not statistically significant (p = 0.35, α = 0.1).93 AML patients had PICC lines for an average of 82.7 days and an infection rate of 1.82 infections per thousand line days. 441 non-AML patients had PICC lines for an average of 73.6 days and an infection rate of 1.26 infections per thousand line days. The higher infection rate in AML patients is statistically significant (p = 0.09, α = 0.1).
Conclusions
Both BMT patients and AML patients have a high risk of infection due to their immunocompromised status. AML patients do have a higher rate of infection compared to the overall oncology cohort, however BMT patients do not have a higher rate of infection. This may be due to improved care for their PICC during hospitalization for their bone marrow transplantation.